Bioniz therapeutics
WebAug 4, 2024 · NCT03239392: In April 2024, Bioniz Therapeutics initiated a dose-ranging study of Intravenous BNZ132-1-40 in patients with Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell ... WebLegal Name Bioniz, Llc. Company Type For Profit. Contact Email [email protected]. Phone Number (949)273-6000. Bioniz is an emerging biotechnology/drug development company focused on discovering small …
Bioniz therapeutics
Did you know?
WebBioniz Therapeutics has raised a total of $14.3M in funding over 3 rounds. Their latest funding was raised on Aug 1, 2016 from a Series A round. Bioniz Therapeutics is funded by 4 investors. Takeda Ventures and Signatures Capital are the most recent investors. WebInstructions for use Sinupret recommends taking 2 drops or 50 drops of the drug three times a day. Dragee swallowed whole, without biting and squeezing a small volume of liquid. …
WebAug 4, 2024 · Bioniz Therapeutics: ClinicalTrials.gov Identifier: NCT03239392 Other Study ID Numbers: BNZ1-CT-201 : First Posted: August 4, 2024 Key Record Dates: Last Update Posted: May 25, 2024 Last Verified: April 2024 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Yes: Supporting Materials: ... WebMay 17, 2024 · Bioniz is building a pipeline of novel peptide therapeutics which selectively inhibit functionally redundant cytokines, while leaving the rest of the cytokine network unaffected. The company's lead product is BNZ-1, which targets cutaneous T-cell lymphoma and alopecia areata by simultaneously inhibiting cytokines IL-2, IL-9 and IL-15.
WebJul 31, 2024 · May 24, 2024 updated by: Bioniz Therapeutics. A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma. This study is an open-label, multi-center, dose-ranging study to characterize the safety, tolerability, preliminary efficacy, and PK/PD of … WebBioniz Therapeutics General Information. Description. Developer of multi-cytokine inhibitory therapeutics designed to address immuno-inflammatory diseases and cancer …
WebNov 5, 2024 · IRVINE, Calif., Nov. 5, 2024 /PRNewswire/ -- Bioniz Therapeutics, Inc. ("Bioniz") today announced an oral presentation at the 62nd ASH Annual Meeting and Exposition of positive safety and efficacy data from the company's Phase 1/2 clinical study of BNZ-1 for the treatment of refractory cutaneous T-cell lymphoma (rCTCL), a rare, …
WebBioniz Therapeutics has raised a total of $14.3M in funding over 3 rounds. Their latest funding was raised on Aug 1, 2016 from a Series A round. Bioniz Therapeutics is … shared coaching planWebJan 9, 2024 · About Bioniz Therapeutics . Bioniz Therapeutics is a clinical-stage biopharmaceutical company leading the discovery and development of first-in-class multi-cytokine inhibitory peptide therapeutics to address immuno-inflammatory diseases and cancer. Bioniz leverages its world-class expertise in cytokine biology, originated in … shared cockpitWebBioniz Therapeutics is a biopharmaceutical company. It is engaged in the discovery and development of peptide therapeutics that selectively and simultaneously inhibit multiple … pool sand filter 08234WebAbout Bioniz. Bioniz is a clinical-stage biopharmaceutical company developing precision cytokine targeted therapies for the treatment of immuno-inflammatory diseases. pool sand filter air leakWebJan 4, 2024 · Bioniz Therapeutics is a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class peptide-based multi-cytokine inhibitors for the … shared cnnWebMar 24, 2024 · Bioniz Therapeutics is a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class peptide-based multi-cytokine inhibitors for the … pool sand filter 30000 galWebEquillium, with only one asset in its pipeline thanks to an in-licensing deal, is expanding its drug development efforts via the acquisition of Bioniz Therapeutics. Equillium will pay up to $329 ... shared coal ship loaders